4:03 PM
 | 
Sep 17, 2018
 |  BC Extra  |  Politics & Policy

Senate passes 'pay-for-delay' bill for biosimilars

The Senate passed a bill Monday that includes a provision to make it more difficult for branded drugmakers to strike “pay-for-delay” deals with biologic and biosimilar companies.

The language aims to modernize reporting requirements for biologics and biosimilars by requiring patent settlements with branded drugmakers...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >